Development of Psoriasis During Treatment with Weekly Dupilumab for Refractory Hailey-Hailey Disease
Main Article Content
Keywords
dupilumab, benign familial pemphigus, psoriasis, hailey hailey disease
Abstract
Hailey-Hailey Disease is a rare inherited disease that is often to treat. Several case reports have discussed the potential role of dupilumab for the treatment of Hailey-Hailey Disease. Our case presents a patient who required more frequent dosing of dupilumab than previously reported to manage his symptoms. His course was further complicated by development of psoriatic lesions which were successfully treated with topicals steroids, allowing continuation of dupilumab.
References
2. Alamon-Reig F, Serra-Garcia L, Bosch-Amate X, Riquelme-Mc Loughlin C, Mascaro JM, Jr. Dupilumab in Hailey-Hailey disease: a case series. J Eur Acad Dermatol Venereol. 2022.
3. Licata G, Buononato D, Calabrese G, et al. A case of Hailey-Hailey disease successfully treated with dupilumab. Int J Dermatol. 2022.
4. Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: A systematic review. J Am Acad Dermatol. 2022;86(3):708-709.
5. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-2348.
6. Deleuran M, Thaci D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377-388.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.